LIMINATUS PHARMA, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
LIMINATUS PHARMA, INC. (LIMN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$294.08 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- LIMINATUS PHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$102.13K.
- LIMINATUS PHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$191.96K, a 258.03% decline year-over-year.
- LIMINATUS PHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $23.06K, a 22.90% decline year-over-year.
- LIMINATUS PHARMA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$2.01M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$102.13K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$294.08K 10-Q · filed 2026-08-14 | -$271.02K derived: sum of 3 quarters · filed 2026-08-14 | -$2.29M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$191.96K S-1 · filed 2026-06-24 | -$168.89K derived: sum of 2 quarters · filed 2026-06-24 | -$2.18M derived: sum of 3 quarters · filed 2026-06-24 | -$4.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $23.06K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$1.99M derived: sum of 2 quarters · filed 2026-06-24 | -$4.16M derived: sum of 3 quarters · filed 2026-08-14 | -$4.04M S-1 · filed 2026-06-24 |
| 2025-09-30 | -$2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$4.18M derived: sum of 2 quarters · filed 2026-08-14 | -$4.06M 10-Q · filed 2025-11-14 | -$4.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$2.16M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$2.04M 10-Q · filed 2026-08-14 | -$2.01M derived: sum of 3 quarters · filed 2026-08-14 | -$2.03M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $121.47K S-1 · filed 2026-06-24 | $151.38K derived: sum of 2 quarters · filed 2026-06-24 | $133.34K derived: sum of 3 quarters · filed 2026-06-24 | |
| 2024-12-31 | $29.92K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $11.88K derived: sum of 2 quarters · filed 2026-06-24 | -$10.75K S-1 · filed 2026-06-24 | |
| 2024-09-30 | -$18.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$40.66K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$22.62K 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |